Blockage of CacyBP inhibits macrophage recruitment and improves anti-PD-1 therapy in hepatocellular carcinoma

BACKGROUND: Despite remarkable advancements in cancer immunotherapy, the overall response rate to anti-programmed cell death-1 (anti-PD-1) therapy in hepatocellular carcinoma (HCC) patients remains low. Our previous study has demonstrated the critical role of CacyBP/SIP (Calcyclin-Binding Protein an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jialiang, Zhang, Xiaoyu, Ma, Xinyi, Chen, Dongmei, Cai, Meina, Xiao, Lexin, Li, Jing, Huang, Zexuan, Huang, Yuehua, Lian, Yifan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652496/
https://www.ncbi.nlm.nih.gov/pubmed/37968706
http://dx.doi.org/10.1186/s13046-023-02885-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652496/
https://www.ncbi.nlm.nih.gov/pubmed/37968706
http://dx.doi.org/10.1186/s13046-023-02885-w

Ejemplares similares